One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits

We sought to assess postoperative outcome after pneumonectomy after neoadjuvant therapy in patients with non-small cell lung cancer. This retrospective study included 100 patients treated from January 1989 through December 2003 for a primary lung cancer in whom pneumonectomy had been performed after...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 2005-08, Vol.130 (2), p.416-425
Hauptverfasser: Doddoli, Christophe, Barlesi, Fabrice, Trousse, Delphine, Robitail, Stéphane, Yena, Sadio, Astoul, Philippe, Giudicelli, Roger, Fuentes, Pierre, Thomas, Pascal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 425
container_issue 2
container_start_page 416
container_title The Journal of thoracic and cardiovascular surgery
container_volume 130
creator Doddoli, Christophe
Barlesi, Fabrice
Trousse, Delphine
Robitail, Stéphane
Yena, Sadio
Astoul, Philippe
Giudicelli, Roger
Fuentes, Pierre
Thomas, Pascal
description We sought to assess postoperative outcome after pneumonectomy after neoadjuvant therapy in patients with non-small cell lung cancer. This retrospective study included 100 patients treated from January 1989 through December 2003 for a primary lung cancer in whom pneumonectomy had been performed after an induction treatment. Surgical intervention had not been considered initially for the following reasons: N2 disease (stage IIIA, n = 79), doubtful resectability (stage IIIB [T4, N0], n = 19), and M1 disease (stage IV [T2, N0, M1, solitary brain metastasis], n = 2). All patients received a 2-drug platinum-based regimen with a median of 2.5 cycles (range, 2–4 cycles), and 30 had associated radiotherapy (30–45 Gy). There were 55 right and 45 left resections. Overall 30-day and 90-day mortality rates were 12% and 21%, respectively. At multivariate analysis, one inde- pendent prognostic factor entered the model to predict 30-day mortality: postoperative cardiovascular event (relative risk, 45.7; 95% confidence interval, 3.7–226.7; P = .001). Four variables predicted 90-day mortality: age of more than 60 years (relative risk, 5.06; 95% confidence interval, 1.47–17.48; P = .01), male sex (relative risk, 8.25; 95% confidence interval, 1.01–67.34; P = .049), postoperative respiratory event (relative risk, 3.64; 95% confidence interval, 1.14–9.37; P = .007), and postoperative cardiovascular event (relative risk, 7.84; 95% confidence interval, 3.12–19.71; P < .001). Estimated overall survivals in 90-day survivors were 35% (range, 29%-41%) and 25% (range, 19.3%-30.7%) at 3 and 5 years, respectively. At multivariate analysis, one independent prognostic factor entered the model: pathologic stage III-IV residual disease (relative risk, 1.89; 95% confidence interval, 1.09–3.26; P = .022). Pneumonectomy after induction therapy is a high-risk procedure, the survival benefit of which appears uncertain.
doi_str_mv 10.1016/j.jtcvs.2004.11.022
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68444991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022522304016265</els_id><sourcerecordid>68444991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4452-519dca5acb32d39361103fcbe14d9e96f6358c1c53d8c7c30859a91d370135d53</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EotvCEyAhX4BTgifOPyNxqCoKSJV6AYmb5diTrpfEXmxnqz4Fr4zTXak3Lrb16TffjL8h5A2wEhi0H3flLulDLCvG6hKgZFX1jGyAia5o--bXc7JhWSqaquJn5DzGHWOsYyBekjNoWdfVrNuQv7cO6XZxJqCh2ruIekn2gHTvcJm9Q538bDFSNSYM1Dqz6GS9o2mLQe0f6OgDdd4VcVbTRDXmY1rcHdXKaQyf6KWjy_pKyjo6qGmV6YDpHtHRYOPvbO1MVhyONsVX5MWopoivT_cF-Xn95cfVt-Lm9uv3q8ubQtd1kz8FwmjVKD3wynDBWwDGRz0g1EagaMeWN70G3XDT605z1jdCCTA8B8Ab0_AL8v7ouw_-z4IxydnGdXrl0C9Rtn1d10JABvkR1MHHGHCU-2BnFR4kMLnuQe7k4x7kugcJIHPouertyX4ZZjRPNafgM_DuBKio1TSGnIuNT1wHdZf7Z-7Dkdvau-29DSgfg862sLaNwJmsZA1tJj8fScyxHSwGGbXFnLbJVTpJ4-1_R_4HC9S3fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68444991</pqid></control><display><type>article</type><title>One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Doddoli, Christophe ; Barlesi, Fabrice ; Trousse, Delphine ; Robitail, Stéphane ; Yena, Sadio ; Astoul, Philippe ; Giudicelli, Roger ; Fuentes, Pierre ; Thomas, Pascal</creator><creatorcontrib>Doddoli, Christophe ; Barlesi, Fabrice ; Trousse, Delphine ; Robitail, Stéphane ; Yena, Sadio ; Astoul, Philippe ; Giudicelli, Roger ; Fuentes, Pierre ; Thomas, Pascal</creatorcontrib><description>We sought to assess postoperative outcome after pneumonectomy after neoadjuvant therapy in patients with non-small cell lung cancer. This retrospective study included 100 patients treated from January 1989 through December 2003 for a primary lung cancer in whom pneumonectomy had been performed after an induction treatment. Surgical intervention had not been considered initially for the following reasons: N2 disease (stage IIIA, n = 79), doubtful resectability (stage IIIB [T4, N0], n = 19), and M1 disease (stage IV [T2, N0, M1, solitary brain metastasis], n = 2). All patients received a 2-drug platinum-based regimen with a median of 2.5 cycles (range, 2–4 cycles), and 30 had associated radiotherapy (30–45 Gy). There were 55 right and 45 left resections. Overall 30-day and 90-day mortality rates were 12% and 21%, respectively. At multivariate analysis, one inde- pendent prognostic factor entered the model to predict 30-day mortality: postoperative cardiovascular event (relative risk, 45.7; 95% confidence interval, 3.7–226.7; P = .001). Four variables predicted 90-day mortality: age of more than 60 years (relative risk, 5.06; 95% confidence interval, 1.47–17.48; P = .01), male sex (relative risk, 8.25; 95% confidence interval, 1.01–67.34; P = .049), postoperative respiratory event (relative risk, 3.64; 95% confidence interval, 1.14–9.37; P = .007), and postoperative cardiovascular event (relative risk, 7.84; 95% confidence interval, 3.12–19.71; P &lt; .001). Estimated overall survivals in 90-day survivors were 35% (range, 29%-41%) and 25% (range, 19.3%-30.7%) at 3 and 5 years, respectively. At multivariate analysis, one independent prognostic factor entered the model: pathologic stage III-IV residual disease (relative risk, 1.89; 95% confidence interval, 1.09–3.26; P = .022). Pneumonectomy after induction therapy is a high-risk procedure, the survival benefit of which appears uncertain.</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/j.jtcvs.2004.11.022</identifier><identifier>PMID: 16077407</identifier><identifier>CODEN: JTCSAQ</identifier><language>eng</language><publisher>Philadelphia, PA: Mosby, Inc</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration &amp; dosage ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - therapy ; Combined Modality Therapy ; Female ; Humans ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Medical sciences ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Platinum Compounds - administration &amp; dosage ; Pneumology ; Pneumonectomy ; Retrospective Studies ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart ; Survival Analysis ; Treatment Outcome ; Tumors of the respiratory system and mediastinum</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 2005-08, Vol.130 (2), p.416-425</ispartof><rights>2005 The American Association for Thoracic Surgery</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4452-519dca5acb32d39361103fcbe14d9e96f6358c1c53d8c7c30859a91d370135d53</citedby><cites>FETCH-LOGICAL-c4452-519dca5acb32d39361103fcbe14d9e96f6358c1c53d8c7c30859a91d370135d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jtcvs.2004.11.022$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17147499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16077407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doddoli, Christophe</creatorcontrib><creatorcontrib>Barlesi, Fabrice</creatorcontrib><creatorcontrib>Trousse, Delphine</creatorcontrib><creatorcontrib>Robitail, Stéphane</creatorcontrib><creatorcontrib>Yena, Sadio</creatorcontrib><creatorcontrib>Astoul, Philippe</creatorcontrib><creatorcontrib>Giudicelli, Roger</creatorcontrib><creatorcontrib>Fuentes, Pierre</creatorcontrib><creatorcontrib>Thomas, Pascal</creatorcontrib><title>One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>We sought to assess postoperative outcome after pneumonectomy after neoadjuvant therapy in patients with non-small cell lung cancer. This retrospective study included 100 patients treated from January 1989 through December 2003 for a primary lung cancer in whom pneumonectomy had been performed after an induction treatment. Surgical intervention had not been considered initially for the following reasons: N2 disease (stage IIIA, n = 79), doubtful resectability (stage IIIB [T4, N0], n = 19), and M1 disease (stage IV [T2, N0, M1, solitary brain metastasis], n = 2). All patients received a 2-drug platinum-based regimen with a median of 2.5 cycles (range, 2–4 cycles), and 30 had associated radiotherapy (30–45 Gy). There were 55 right and 45 left resections. Overall 30-day and 90-day mortality rates were 12% and 21%, respectively. At multivariate analysis, one inde- pendent prognostic factor entered the model to predict 30-day mortality: postoperative cardiovascular event (relative risk, 45.7; 95% confidence interval, 3.7–226.7; P = .001). Four variables predicted 90-day mortality: age of more than 60 years (relative risk, 5.06; 95% confidence interval, 1.47–17.48; P = .01), male sex (relative risk, 8.25; 95% confidence interval, 1.01–67.34; P = .049), postoperative respiratory event (relative risk, 3.64; 95% confidence interval, 1.14–9.37; P = .007), and postoperative cardiovascular event (relative risk, 7.84; 95% confidence interval, 3.12–19.71; P &lt; .001). Estimated overall survivals in 90-day survivors were 35% (range, 29%-41%) and 25% (range, 19.3%-30.7%) at 3 and 5 years, respectively. At multivariate analysis, one independent prognostic factor entered the model: pathologic stage III-IV residual disease (relative risk, 1.89; 95% confidence interval, 1.09–3.26; P = .022). Pneumonectomy after induction therapy is a high-risk procedure, the survival benefit of which appears uncertain.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Platinum Compounds - administration &amp; dosage</subject><subject>Pneumology</subject><subject>Pneumonectomy</subject><subject>Retrospective Studies</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EotvCEyAhX4BTgifOPyNxqCoKSJV6AYmb5diTrpfEXmxnqz4Fr4zTXak3Lrb16TffjL8h5A2wEhi0H3flLulDLCvG6hKgZFX1jGyAia5o--bXc7JhWSqaquJn5DzGHWOsYyBekjNoWdfVrNuQv7cO6XZxJqCh2ruIekn2gHTvcJm9Q538bDFSNSYM1Dqz6GS9o2mLQe0f6OgDdd4VcVbTRDXmY1rcHdXKaQyf6KWjy_pKyjo6qGmV6YDpHtHRYOPvbO1MVhyONsVX5MWopoivT_cF-Xn95cfVt-Lm9uv3q8ubQtd1kz8FwmjVKD3wynDBWwDGRz0g1EagaMeWN70G3XDT605z1jdCCTA8B8Ab0_AL8v7ouw_-z4IxydnGdXrl0C9Rtn1d10JABvkR1MHHGHCU-2BnFR4kMLnuQe7k4x7kugcJIHPouertyX4ZZjRPNafgM_DuBKio1TSGnIuNT1wHdZf7Z-7Dkdvau-29DSgfg862sLaNwJmsZA1tJj8fScyxHSwGGbXFnLbJVTpJ4-1_R_4HC9S3fw</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Doddoli, Christophe</creator><creator>Barlesi, Fabrice</creator><creator>Trousse, Delphine</creator><creator>Robitail, Stéphane</creator><creator>Yena, Sadio</creator><creator>Astoul, Philippe</creator><creator>Giudicelli, Roger</creator><creator>Fuentes, Pierre</creator><creator>Thomas, Pascal</creator><general>Mosby, Inc</general><general>AATS/WTSA</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits</title><author>Doddoli, Christophe ; Barlesi, Fabrice ; Trousse, Delphine ; Robitail, Stéphane ; Yena, Sadio ; Astoul, Philippe ; Giudicelli, Roger ; Fuentes, Pierre ; Thomas, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4452-519dca5acb32d39361103fcbe14d9e96f6358c1c53d8c7c30859a91d370135d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Platinum Compounds - administration &amp; dosage</topic><topic>Pneumology</topic><topic>Pneumonectomy</topic><topic>Retrospective Studies</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doddoli, Christophe</creatorcontrib><creatorcontrib>Barlesi, Fabrice</creatorcontrib><creatorcontrib>Trousse, Delphine</creatorcontrib><creatorcontrib>Robitail, Stéphane</creatorcontrib><creatorcontrib>Yena, Sadio</creatorcontrib><creatorcontrib>Astoul, Philippe</creatorcontrib><creatorcontrib>Giudicelli, Roger</creatorcontrib><creatorcontrib>Fuentes, Pierre</creatorcontrib><creatorcontrib>Thomas, Pascal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doddoli, Christophe</au><au>Barlesi, Fabrice</au><au>Trousse, Delphine</au><au>Robitail, Stéphane</au><au>Yena, Sadio</au><au>Astoul, Philippe</au><au>Giudicelli, Roger</au><au>Fuentes, Pierre</au><au>Thomas, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>2005-08</date><risdate>2005</risdate><volume>130</volume><issue>2</issue><spage>416</spage><epage>425</epage><pages>416-425</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><coden>JTCSAQ</coden><abstract>We sought to assess postoperative outcome after pneumonectomy after neoadjuvant therapy in patients with non-small cell lung cancer. This retrospective study included 100 patients treated from January 1989 through December 2003 for a primary lung cancer in whom pneumonectomy had been performed after an induction treatment. Surgical intervention had not been considered initially for the following reasons: N2 disease (stage IIIA, n = 79), doubtful resectability (stage IIIB [T4, N0], n = 19), and M1 disease (stage IV [T2, N0, M1, solitary brain metastasis], n = 2). All patients received a 2-drug platinum-based regimen with a median of 2.5 cycles (range, 2–4 cycles), and 30 had associated radiotherapy (30–45 Gy). There were 55 right and 45 left resections. Overall 30-day and 90-day mortality rates were 12% and 21%, respectively. At multivariate analysis, one inde- pendent prognostic factor entered the model to predict 30-day mortality: postoperative cardiovascular event (relative risk, 45.7; 95% confidence interval, 3.7–226.7; P = .001). Four variables predicted 90-day mortality: age of more than 60 years (relative risk, 5.06; 95% confidence interval, 1.47–17.48; P = .01), male sex (relative risk, 8.25; 95% confidence interval, 1.01–67.34; P = .049), postoperative respiratory event (relative risk, 3.64; 95% confidence interval, 1.14–9.37; P = .007), and postoperative cardiovascular event (relative risk, 7.84; 95% confidence interval, 3.12–19.71; P &lt; .001). Estimated overall survivals in 90-day survivors were 35% (range, 29%-41%) and 25% (range, 19.3%-30.7%) at 3 and 5 years, respectively. At multivariate analysis, one independent prognostic factor entered the model: pathologic stage III-IV residual disease (relative risk, 1.89; 95% confidence interval, 1.09–3.26; P = .022). Pneumonectomy after induction therapy is a high-risk procedure, the survival benefit of which appears uncertain.</abstract><cop>Philadelphia, PA</cop><pub>Mosby, Inc</pub><pmid>16077407</pmid><doi>10.1016/j.jtcvs.2004.11.022</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-5223
ispartof The Journal of thoracic and cardiovascular surgery, 2005-08, Vol.130 (2), p.416-425
issn 0022-5223
1097-685X
language eng
recordid cdi_proquest_miscellaneous_68444991
source MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Antineoplastic Agents - administration & dosage
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Combined Modality Therapy
Female
Humans
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Medical sciences
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Platinum Compounds - administration & dosage
Pneumology
Pneumonectomy
Retrospective Studies
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the heart
Survival Analysis
Treatment Outcome
Tumors of the respiratory system and mediastinum
title One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A49%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=One%20hundred%20consecutive%20pneumonectomies%20after%20induction%20therapy%20for%20non-small%20cell%20lung%20cancer:%20An%20uncertain%20balance%20between%20risks%20and%20benefits&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Doddoli,%20Christophe&rft.date=2005-08&rft.volume=130&rft.issue=2&rft.spage=416&rft.epage=425&rft.pages=416-425&rft.issn=0022-5223&rft.eissn=1097-685X&rft.coden=JTCSAQ&rft_id=info:doi/10.1016/j.jtcvs.2004.11.022&rft_dat=%3Cproquest_cross%3E68444991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68444991&rft_id=info:pmid/16077407&rft_els_id=S0022522304016265&rfr_iscdi=true